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Abstract
Background: Hepatic steatosis is an established risk factor for complications following major hepatic resection.
Pharmacological options to reverse steatosis prior to surgery, however, are lacking. We hypothesized that treatment
with the pharmacologic tumor necrosis factor-a converting enzyme (TACE)-inhibitor Marimastat would reverse established
steatosis, leading to improved outcome following hepatectomy.
Methodology/Principal Findings: C57BL/6 male mice were fed a high fat diet for 9 weeks to establish obesity, hepatic
steatosis and insulin resistance, and were administered either Marimastat or vehicle for an additional 2 or 4 weeks. Leptin
deficient, hyperinsulinemic ob/ob mice were treated with Marimastat for 4 weeks. Hepatic steatosis was quantified by
magnetic resonance spectroscopy and confirmed by histology. After two weeks, Marimastat-treated animals significantly
improved surrogate markers for insulin sensitivity and liver histology, and experienced a 66% decrease in steatosis
(P= 0.010). These findings were confirmed in ob/ob mice. Transcripts related to fatty acid synthesis were significantly
downregulated in Marimastat-treated animals. Following pre-treatment with Marimastat or vehicle for two weeks, high fat
fed C57BL/6 mice were subjected to two-thirds hepatectomy. Post-operative liver injury as quantified by serum aspartate
aminotransferase levels and alanine aminotransferase levels was significantly decreased by 57% (P= 0.020) and 44%
(P= 0.032) respectively, compared to controls.
Conclusion/Significance: Treatment with the TACE-inhibitor Marimastat improved surrogate markers for insulin sensitivity
and reversed steatosis in mouse models of diet-induced obesity and leptin deficiency, thereby attenuating post-operative
injury following hepatectomy. This may suggest a potential therapeutic role in patients with fatty liver disease; especially
those who need to undergo hepatic resection.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is one of the hallmarks
of the metabolic syndrome and is a significant and increasingly more
common cause of liver failure [1,2]. NAFLD is characterized by an
accumulation of triglycerides in hepatocytes (hepatic steatosis), and,
together with lipotoxic injury, may lead to hepatocellular injury and
inflammation (non-alcoholic steatohepatitis), advanced fibrosis, and
ultimately liver failure [3–5]. Although its prevalence in both
children and adults is increasing worldwide [1,2], the mechanisms
underlying the pathogenesis of NAFLD remain elusive.
Steatosis is an established risk factor for primary non-function of
hepatic allografts [6] and for complications following major
hepatic resection [7]. Patients with steatosis have up to a twofold
increased risk of postoperative complications, and those with
excessive steatosis (.30%) have an almost threefold increased risk
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of death [7]. Approximately 20% of patients undergoing liver
resection and up to 25% of liver donors have some degree of
steatosis, indicating the need for pharmacological intervention [8].
Currently, the cornerstone of clinical management is weight loss
through diet and exercise [9]. In reality, however, surgical
management usually does not allow time for such dramatic life
style changes, justifying the search for a pharmacologic approach.
Novel evidence suggests that vitamin E therapy and pioglitazone
may be of use in patients with non-alcoholic steatohepatitis [10].
Pharmacological options to reverse steatosis prior to surgery,
however, are lacking.
Insulin resistance and the resultant hyperinsulinemia, common-
ly associated with the metabolic syndrome, are involved in the
imbalance of formation and utilization of free fatty acids leading to
steatosis [11,12]. In addition, visceral and hepatic lipid accumu-
lation may activate inflammatory gene networks, suggesting a
causal function of inflammation in the pathogenesis of the
metabolic syndrome [13]. Tumor necrosis factor (TNF)-a is an
inflammatory cytokine involved in linking nutrient availability to
innate immune activation and is the major negative regulator of
the insulin receptor pathway [14,15] TNF-a release from the
plasma membrane through its ectodomain shedding is mediated
by TNF-a converting enzyme (TACE, also known as ADAM17
and CD156b), which belongs to the disintegrin and metallopro-
teinase family of zinc-metalloproteinases [16,17] TACE is
endogenously inhibited by tissue inhibitor of metalloproteinase
(TIMP)-3 [18], and may be activated by metabolic stimuli such as
hyperinsulinemia [19]. Mice deficient in TIMP-3 demonstrate
elevated levels of TNF-a and develop insulin resistance and
hepatic steatosis, mediated by increased TACE activity [20,21]. In
contrast, pharmacologic TACE-inhibition abrogates the inflam-
matory response and has been demonstrated to improve insulin
resistance [22,23].
The TACE/TIMP-3 system has recently emerged as a novel
mediator between metabolic stimuli and innate immunity;
however, the effects of pharmacologic TACE-inhibition on insulin
resistance and hepatic steatosis remain to be established. We
hypothesized that treatment with Marimastat would ameliorate
insulin resistance and reverse established hepatic steatosis,
potentially resulting in improved surgical outcome following
hepatectomy in murine models of diet-induced obesity, hepatic
steatosis and insulin resistance.
Materials and Methods
Ethics statement
Animal protocols complied with the National Institutes of
Health Animal Research Advisory Committee guidelines and were
approved by the Children’s Hospital Boston Animal Care and Use
Committee (protocol no. A06-08-065R).
Animal experiments
Mice were housed 4 or 5 animals per cage on paper chip
bedding in a barrier room with regulated temperature
(21uC61.6uC), humidity (45%610%), and an alternating 12-hour
light and dark cycle. The animals had free access to water and
study diets, but a pair-feeding design was used after animals were
assigned to the treatments to avoid bias resulting from a potential
decreased caloric intake [24,25].
After an acclimation period of one week, twenty-five C57BL/6
male mice (#000664; Jackson Laboratories, Bar Harbor, ME)
were placed on a high fat diet with 60% of calories derived from
fat (#D12492; Research Diets, New Brunswick, NJ), whereas
another group of five animals that were fed a standard purified
rodent diet containing 10% of calories from fat (#D12450B;
Research Diets) served as controls. Study diets were stored at
280uC and provided fresh each day to avoid lipid peroxidation.
After 9 weeks, five animals from each group were sacrificed and
tissues were analyzed to serve as baseline controls. The remaining
twenty animals on the high fat diet were randomized to receive
either 100 mg/kg of Marimastat (BB-2516, British Biotech, UK)
in 0.45% methylcellulose (Sigma-Aldrich, St. Louis, MO) vehicle
twice daily via orogastric gavage (MAR), or vehicle alone (VEH)
for an additional two or four weeks (n=5 per group). At the end of
the treatment period, animals were sacrificed to evaluate hepatic
steatosis and related parameters (Figure 1A).
In a separate experiment, fifteen B6.V-Lepob/J male mice
(#000632; Jackson Laboratories), commonly referred to as ob/ob
Figure 1. Design of the studies. Hepatic steatosis was induced by placing C57BL/6 mice on a 60% high fat diet for 9 weeks, followed by a two or
four week treatment period with either Marimastat (MAR) or methylcellulose vehicle (VEH) twice daily (A). Leptin deficient ob/ob animals were placed
on a 10% standard fat diet for two weeks, followed by a four week treatment period with either MAR or VEH twice daily (B). The efficacy of Marimastat
on post-operative outcome following reversal of steatosis was evaluated in a model of two-thirds hepatectomy (C). C57BL/6 mice were placed on a
60% high fat diet, followed by two weeks of treatment with MAR or VEH twice daily. Mice were then subjected to a two-thirds hepatectomy, and
sacrificed postoperatively to assess hepatic injury.
doi:10.1371/journal.pone.0025587.g001
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mice [26,27], were acclimatized for one week and placed on a
standard purified rodent diet containing 10% of calories from fat.
After two weeks, five animals were sacrificed to serve as base-line
controls and the remaining animals were randomized to receive
either Marimastat twice daily (MAR) or vehicle alone (VEH) for
an additional four weeks (Figure 1B).
The efficacy of Marimastat to reverse steatosis and improve
surgical outcome was studied using fifty C57BL/6 male mice
placed on a similar high fat diet for 9 weeks, followed by two weeks
of treatment with either Marimastat twice daily (MAR) or vehicle
alone (VEH) while remaining on the high fat diet. After thirteen
days, animals were withheld treatment for 24 hours to avoid
potential inhibitory effects on liver regeneration [28]. The
following morning, mice underwent the surgical removal of two-
thirds of the liver under isoflurane anesthesia. The left upper, right
upper, and left lower lobes of the liver were ligated with 5-0 silk
ties (Ethicon, Somerville, NJ) and then excised, as previously
described [29]. Animals were sacrificed either immediately to
serve as controls, or after one, two, four and eight days to evaluate
liver regeneration and related parameters (Figure 1C).
Sample collection and serum biochemistry
At the end of the feeding experiments, mice were fasted for
6 hours. Glucose concentration was determined from tail vein
blood using the OneTouch UltraSmart Blood Glucose Monitoring
System (LifeScan, Milpitas, CA). Serum was delivered to the
Clinical Laboratory at Children’s Hospital Boston for analysis.
The left lateral lobe was excised and collected for magnetic
resonance (MR) spectroscopy analysis. White adipose tissue was
dissected according to previously defined anatomic landmarks
[24,25]. A white adipose tissue fat-index was calculated using the
sum of the individual fat pads as a percentage of the eviscerated
body weight [24,25].
Surrogate index of insulin sensitivity and resistance
Insulin levels were measured using a rat/mouse insulin enzyme-
linked immunosorbent assay kit (#EZRMI-13K; Millipore, St.
Charles, MO). A surrogate index for insulin sensitivity was calculated
using the log of homeostasis assessment (HOMA) and Quantitative
insulin-sensitivity check index (QUICKI) formulas [24,25,30].
Histology
Paraffin-embedded sections of the liver were stained by
hematoxylin and eosin and periodic acid Schiff’s/diastase to
examine cellular architecture, glycogen deposition and lipid
accumulation. Frozen tissue sections were stained with Oil Red-
O to detect fat. A pathologist blinded to the treatment groups
conducted a histological analysis of the liver sections.
Magnetic resonance imaging
Magnetic resonance (MR) spectroscopy analysis was used to
objectively quantify hepatic fat fraction as described previously
[24,25]. Briefly, samples were thawed at room temperature for
1 hour prior to analysis, blotted free of excess water and
connective tissue, and placed in 5 mm diameter glass tubes for
MR spectroscopy. An 8.5 T vertical bore magnet (DRX system,
Bruker Instruments, Billerica, MA) was used for spectroscopic
measurements of fat and water resonances. Specifically, a point
resolved echo spectroscopic acquisition was applied to homoge-
nous regions of liver, as identified from fast low angle shot images
of the liver specimen. Voxel volumes interrogated spectroscopi-
cally with the point resolved echo spectroscopic sequence were
2 mm3. The repetition and echo times were 8 s and 12 ms,
respectively, and 16 signal averages were acquired per spectrum.
The water resonance and the methylene/methyl resonances were
numerically integrated using the manufacturer supplied Paravision
4.0 software (Bruker Instruments). The methylene/methyl area
was divided by the sum of the methylene/methyl area plus the
water area to obtain the MR spectroscopy parameter representing
hepatic fat fraction used for group comparisons.
Cytokine and adipokine analysis
Serum levels of Adiponectin (#EZMADP-60K; Millipore),
Leptin (#EZML-82K; Millipore), soluble TNF-a receptor II
(p75) (#MRT20; Quantikine, R&D Systems, Minneapolis, MN)
and IL-6 (#M6000B; Quantikine) were determined using
commercial enzyme-linked immunosorbent assay kits. Optical
density was read at 450 nm and analyzed with Softmax PRO
Software (Molecular Devices, Sunnyvale, CA).
Very low density lipoprotein secretion assay
After being fasted for 6 hours, mice were injected with 500 mg/
kg tyloxapol (Triton-1339; Sigma-Aldrich) dissolved in saline at a
concentration of 150 mg/mL via the tail vein. Both lipolysis and
tissue uptake of lipoproteins are completely inhibited in mice
under these conditions, and the accumulation of triglyceride in
serum after injection of tyloxapol can be used to estimate rates of
secretion of very low density lipoprotein [31]. Tail bleeds were
performed just before injection (t0) and 45 and 90 min following
injection. Serum was delivered to the Clinical Laboratory at
Children’s Hospital Boston for analysis of triglyceride levels. The
slope of the line denotes the rate of VLDL production.
TACE activity assay
Determination of TACE activity was performed using a
commercially available a-secretase activity assay according to
manufacturer’s instructions (#FP001; R&D Systems, Minneapolis,
MN). Briefly, 10 mL of recombinant human (#903-ADB; R&D
Systems) and mouse (#2978-AD; R&D Systems) TACE were used
as standards on a 96-well plate in triplicates, and increasing doses
of Marimastat dissolved in H2O were added. After 1 hour, a
TACE-specific peptide conjugated to the reporter molecules
EDANS and DABCYL was added. In the uncleaved form,
fluorescent emissions from EDANS were quenched by the physical
proximity of the DABCYL moiety, which exhibits maximal
absorption at the same wavelength (495 nm). Cleavage of the
peptide by TACE physically separates the EDANS and DABCYL
reporter molecules, allowing for the release of a fluorescent signal.
The level of TACE enzymatic activity was proportional to the
fluorometric reaction, measured at room temperature using the
Wallac Victor2 Multilabel Counter (Perkin Elmer, Waltham, MA);
with excitation at 355 nm, and emission at 510 nm.
Analysis of mRNA expression
Isolation of mRNA, reverse transcription and quantitative real-
time RT-PCR were performed as described previously [29,34].
Relative transcript levels of genes of interest were quantified by
real-time RT-PCR on a LightCycler 1.5 instrument (Roche,
Mannheim, Germany) using the TaqMan methodology. TaqMan
probes (dual-labeled with 59-FAM and 39-TAMRA) and primers
were designed based on published sequences (Table 1) using the
Primer Express software (Perkin Elmer), synthesized at MWG
Biotech AG (Ebersberg, Germany), or acquired commercially (Life
Technologies Corporation, Carlsbad, CA) [29,34]. The house-
keeping gene beta-2 microglobulin (b2MG) was amplified in
parallel reactions for normalization.
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Statistical analyses
Data are expressed as means 6 standard error of the mean
(SEM). Differences between two groups were assessed using the
unpaired two-tailed Student’s t test, applying Welch’s correction
when necessary. For non-parametric data the Mann-Whitney U
test was used. Data sets involving more than two groups were
assessed by analysis of variance. P,0.05 was considered
statistically significant. All data were collected in a computerized
Microsoft Excel database (Microsoft Inc., Redmond, WA). The
analysis was performed with SPSS version 16.0 (SPSS Inc.,
Chicago, IL) statistical software, and figures were created using
GraphPad Prism version 5.0 (GraphPad Software Inc., La Jolla,
CA) software.
Results
Marimastat treatment reduced diet-induced
hepatomegaly and normalized gross macroscopic
appearance of livers from diet-induced obese mice
C57BL/6 animals fed a high fat diet for 9 weeks, followed by
two or four weeks of treatment with Marimastat demonstrated
subtle body weight loss, which was only significant after four weeks
(Figure 2A). Body weights of ob/ob animals fed a normal fat diet
followed by a four week course of Marimastat treatment remained
unchanged throughout the study (Figure 2A). White adipose
tissue fat index, as a measure of obesity, significantly decreased
following Marimastat treatment in diet-induced obese mice as well
as in ob/ob mice with 45% and 13%, respectively (P=0.001 and
P=0.034; Figure 2B). Macroscopic appearance of livers from
C57BL/6 mice fed a 10% fat purified rodent diet for 9 weeks
demonstrated normal macroscopic liver appearance (Figure 2B;
left upper pane). Baseline animals that were switched to a 60% fat
diet for 9 weeks developed severe steatosis, indicated by liver
enlargement and pale yellow discoloring (Figure 2B; left middle
panel). Two and four weeks of Marimastat treatment resulted in
significant improvement of macroscopic appearance (Figure 2B;
middle panels), similar to the baseline control liver. Livers from
vehicle treated mice remained pale yellow, indicative of fatty
changes (Figure 2B; upper panels). Because of the marked
differences already after two weeks, we present the data from this
earlier time point throughout the rest of the manuscript. Ob/ob
mice experienced severe liver enlargement and pale yellow
discoloration, indicative for steatosis (left lower panel). Four weeks
of Marimastat treatment resulted in minor improvement of
macroscopic appearance compared to vehicle treated controls
(lower panels). In both animal models, Marimastat treatment
decreased liver to body weight ratios suggesting attenuation of
hepatic steatosis (Figure 2C).
Marimastat reversed hepatic steatosis and improved
surrogate markers for insulin sensitivity in diet-induced
obese mice as well as in leptin-deficient mice
Liver sections from diet-induced obese animals treated for two
weeks with Marimastat showed a significant reduction in steatosis,
as demonstrated by H&E stains, and confirmed with Oil Red O
staining (Figure 3A). Livers from Marimastat treated diet-induced
obese mice exhibited almost normal hepatic architecture, whereas
livers from control animals revealed micro- and macrovesicular
steatosis. In ob/ob mice, Marimastat treatment led to a decrease in
predominantly macrovesicular lipid droplets mainly around the
portal tract, compared to livers from control animals that
exhibited severe macrovesicular steatosis and ballooning
(Figure 3B). To objectively confirm the histological findings,
hepatic fat content was quantified by using MR spectroscopy
(Figure 3A,B bottom panels). Two weeks of Marimastat
treatment of diet-induced obese mice nearly normalized hepatic
fat fraction to 9.064.3%, compared to control animals
(26.162.6%, P=0.010). In ob/ob animals, Marimastat treatment
decreased hepatic fat fraction from 48.862.6% to 34.363.7%
(P=0.019) (Figure 4A). ALT was used as a marker for evaluation
of hepatic injury associated with steatosis (Figure 4B). After two
weeks of treatment with Marimastat, diet-induced obese animals
exhibited a significant decrease of mean serum values for ALT
(54612 IU/L) than did control animals (8967 IU/L; P=0.035).
Following four weeks of Marimastat treatment, ob/ob mice
demonstrated a decreased mean ALT level of 166620 IU/L,
compared to control mice (480687IU/L; P=0.008). In addition,
in the diet-induced obesity model as well as in ob/ob mice
Table 1. Primers and probes used in quantitative real-time RT-PCR.
Target gene 59-Primer TaqMan probe 39-Primer
Acc1 TGTCCGCACTGACTGTAACCA TCTTCCTCAACTTTGTGCCCACGGTC TGCTCCGCACAGATTCTTCA
Fasn CCTGGATAGCATTCCGAACCT CCTGAGGGACCCTACCGCATAGC AGCACATCTCGAAGGCTACACA
Scd1 CAACACCATGGCGTTCCA TGACGTGTACGAATGGGCCCGA GGTGGGCGCGGTGAT
Elovl6 GCGCTGTACGCTGCCTTTAT TCGGCATCTGATGAACAAGCGAGC GCGGCTTCCGAAGTTCAAA
Srebp1 CCAGAGGGTGAGCCTGACAA CAATCAGGACCATGCCGACCTCT AGCCTCTGCAATTTCCAGATCT
Srebp2 GCGGACAACACACAATATCATTG AGCGCTACCGGTCCTCCATCA TGACTAAGTCCTTCAACTCTATGATTTTG
Ppara TGGTTCCTGGTGCCGATTTA TGGTGGTAGATGCCTGCAACCCCA ACTAGCATCCCACTTAATTATGTATCTGAA
LXRa CGACAGAGCTTCGTCCACAA CGGAAAAAGGGCCCAGCCCC GCTCGTTCCCCAGCATTTT
FXR CACGAAGATCAGATTGCTTTGC CAAAGGGTCCGCAGTGGAGGCC CCGCCGAACGAAGAAACA
Mttp [Mm00435015_m1] * * *
Apob [Mm01545156_m1] * * *
Timp3 [Mm00441827_m1] * * *
TACE [Mm00456428_m1] * * *
b2MG CTGATACATACGCCTGCAGAGTTAA GACCGTCTACTGGGATCGAGACATGTG ATGAATCTTCAGAGCATCATGAT
*Not given; commercially acquired from Life Technologies Corporation, Carlsbad, CA.
doi:10.1371/journal.pone.0025587.t001
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Marimastat treatment significantly lowered fasting glucose
(P=0.004 and P=0.041, respectively; Figure 4C) and insulin
(P=0.013 and P=0.039, respectively; Figure 4D) levels, resulting
in improved surrogate markers for insulin sensitivity, as measured
using the log(HOMA) (P,0.001 and P=0.026, respectively;
Figure 4E) and QUICKI (P,0.001 and P=0.0307, respectively;
Figure 4F) formulas. These data indicate that Marimastat
treatment decreased liver injury and improved surrogate markers
for insulin sensitivity in parallel with reversal of steatosis.
Effects of Marimastat on serum adipokine levels and
hepatic fatty acid export
To further explore the metabolic changes after Marimastat
treatment, enzyme-linked immunosorbent assays were performed to
detect serum levels of several adipokines. In both animal models,
Marimastat treatment did not affect serum levels of adiponectin
(Figure 5A), leptin (Figure 5B) or TNF-a receptor II (p75)
(Figure 5C); however, serum levels of IL-6 (Figure 5D) were
significantly increased. Because IL-6 is involved in hepatic export of
triglyceride and cholesterol32, hepatic lipid export rates were
quantified by injection of tyloxapol, an inhibitor of very low-density
lipoprotein hydrolysis. Marimastat treatment did not affect serum
triglyceride levels, indicating that Marimastat did not contribute to
reversal of steatosis by increasing fatty acid export (Figure 5E).
Marimastat treatment decreased TACE activity in vitro
and decreased genetic feedback by Timp3
To confirm inhibition of TACE by Marimastat, an activity
assay was performed. This assay demonstrated efficient inhibition
by Marimastat of both human and mouse recombinant TACE in a
dose-dependent matter (Figure 5F). Quantitative real-time RT-
PCR revealed that hepatic mRNA expression of TACE remained
unchanged following Marimastat treatment; however, transcript
levels of Timp3, the endogenous inhibitor of TACE, were
decreased by 58% (Figure 6A). This suggests that Marimastat
does not inhibit TACE at the gene level, but that inhibition of
TACE activity seizes the need for endogenous inhibition, resulting
in decreased mRNA expression of Timp3.
Hepatic mRNA expression analysis of metabolic genes, as
quantified by real-time RT-PCR
To investigate the changes in metabolic gene signaling induced
by Marimastat treatment, hepatic transcript levels of metabolic
genes were examined using real-time RT-PCR (Figure 6B).
Figure 2. Marimastat treatment resulted in decreased adiposity and liver weights and normalized macroscopic appearance of the
liver. Body weight loss was calculated relative to the weight of each individual animal before initiation of the experiment (A). As a measure of
adiposity, white adipose tissue fat-index was calculated using the sum of the individual fat pads as a percentage of the eviscerated body weight (B).
Liver to body weight ratios were calculated (C). Macroscopic appearance of livers from C57BL/6 and ob/ob mice at time of sacrifice (D). Values
represent the mean6 SEM. Statistical significance is calculated between the VEH and MAR animals (n=5 C57BL/6 and n= 4 ob/ob animals per group;
*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0025587.g002
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Marimastat treatment significantly downregulated genes involved
in fatty acid synthesis such as acetyl-coenzyme a carboxylase alpha
(Acaca), fatty acid synthase (Fasn), stearoyl-coenzyme a desaturase 1
(Scd1), elongation of long chain fatty acids family member 6 (Elovl6)
and sterol regulatory element binding factor 1 (Srefp1), whereas
levels of Srebf2, key transcription factors involved in cholesterol
synthesis, remained unaffected. Marimastat treatment slightly
decreased hepatic transcript levels of genes related to fatty acid
oxidation such as peroxisome proliferator activated receptor alpha
(Ppara), liver X receptor alpha (Nr1h3) and farnesoid X receptor
(Nr1h4), as well as genes involved in triglyceride export such as
microsomal triglyceride transfer protein (Mttp) and apolipoprotein
b (Apob). These findings indicate that the improvement in insulin
resistance, steatosis and inflammation by Marimastat treatment is
associated with inhibition of genes related to fatty acid synthesis,
rather than genes involved in cholesterol synthesis, fatty acid
oxidation or fatty acid export.
Short-term reversal of established steatosis using
Marimastat prior to hepatic resection ameliorated post-
operative liver injury, without affecting regeneration
To further explore the potential clinical benefits of Marimastat,
we studied whether pre-treatment with a short course of
Marimastat to reverse hepatic steatosis and insulin resistance
prior to surgery (as described above) would improve the outcome
of liver resection in the context of fatty liver. To address this
question, we utilized a model of two-thirds hepatectomy, which
was performed in diet-induced obese animals with hepatic
steatosis, pre-treated with Marimastat or not as described above.
Indices of liver regeneration and injury were evaluated as
surrogate predictors of post-operative outcomes. As expected,
two weeks of treatment with Marimastat successfully reversed
steatosis, whereas livers of vehicle-treated animals remained fatty
(Figure 7A). Importantly, speed of liver regeneration was similar
in both groups, as determined by the restoration of liver to body
Figure 3. Marimastat reversed hepatic steatosis in diet-induced obese mice as well as in ob/ob animals, as demonstrated by
histology and magnetic resonance spectroscopy. Representative liver sections stained with hematoxylin and eosin (H&E; top panels; original
magnification 2006), and Oil Red O (ORO; middle panels; original magnification 2006). Hepatic fat fraction was measured by magnetic resonance
spectroscopy (MRS; bottom panels, representative animals). Percent fat content was determined relative to water (100%) by numerical integration of
the areas under the lipid and water peaks. Livers from MAR treated diet-induced obese animals exhibited almost normal hepatic architecture,
whereas VEH livers revealed micro- and macrovesicular steatosis (A). Livers from VEH treated ob/ob mice revealed extensive, predominantly
macrovesicular steatosis (B). MAR treated livers from ob/ob mice, in contrast, showed a decrease in macrovesicular lipid droplets mainly around the
portal tract (B). Histological findings were confirmed with MRS, demonstrating a decrease in fat content in Marimastat-treated animals (A,B bottom
panels).
doi:10.1371/journal.pone.0025587.g003
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weight ratios in the eight days following surgery (Figure 7B).
More strikingly, post-operative liver injury as quantified by AST
(Figure 7C) and ALT (Figure 7D) was significantly decreased by
57% (P=0.020) and 44% (P=0.032), respectively, after 24 hours,
and by 55% (P=0.036) and 45% (P=0.022), respectively, after
48 hours in the group of diet-induced obese animals that had their
steatosis reversed following Marimastat treatment, compared to
controls. In both groups, AST and ALT levels normalized after
four to eight days. Post-operative mortality was limited to one
death in each group related to technical failure. These data
indicate that the reversal of steatosis with Marimastat significantly
attenuated post-operative injury following hepatectomy.
Discussion
The present study aimed to determine the effects of the broad-
spectrum matrix metalloproteinase and TACE-inhibitor Marima-
stat on hepatic steatosis and insulin resistance in murine models of
diet-induced obesity and leptin deficiency. In addition, we studied
the surgical outcome of treated versus untreated animals following
hepatectomy. We demonstrate that Marimastat treatment im-
proves surrogate markers for insulin sensitivity and reverses
steatosis in both animal models by interfering, in all likelihood,
with TACE activation and signaling. The beneficial effects of
steatosis reversal on post-operative outcome by pharmacologic
TACE-inhibition are encouraging, and provide a rationale for
current investigations in the search for a pharmacologic agent to
optimize the steatotic liver prior to surgery. For this indication, a
drug such as Marimastat with its known safety profiles and limited
side-effects would allow rapid transfer to clinical practice.
Previous reports have implicated the TACE/TIMP-3 dyad as a
mediator between metabolic stimuli and innate immunity.
Animals double-heterozygous for the insulin receptor and Timp3
developed spontaneous mild hyperglycemia and hyperinsulinemia
at three months, and overt glucose intolerance and hyperinsulin-
emia at six months [33]. Mice heterozygous for Tace are protected
from diet-induced insulin resistance and diabetes [34], whereas
pharmacologic TACE-inhibition reduced hyperglycemia and
vascular inflammation in diabetic mice heterozygous for the
insulin receptor [33], as well as in fructose-fed rats [23]. In
contrast, Timp3 deficient animals fed a high fat diet for five months
experienced increased TACE activity, became glucose-intolerant
and insulin-resistant and developed severe macrovesicular steatosis
compared to wild-type mice [20]. In another study, mice double-
heterozygous for the insulin receptor and Timp3 that were placed on a
high fat diet developed macrovesicular steatosis and showed a
higher degree of hepatic and adipose tissue inflammation
compared to wild-type mice [21]. In contrast, mice double-
heterozygous for the insulin receptor and Tace had a nearly opposite
phenotype [21]. These data indicate that the interplay between
reduced insulin action and increased TACE activity promotes
diabetes, vascular inflammation and hepatic steatosis. Until now,
the effects of pharmacologic TACE-inhibition on hepatic steatosis
remained to be established. Therefore, we aimed to investigate the
effects of TACE-inhibition in two commonly used models of
obesity and hepatic steatosis. In the diet-induced obesity model, we
Figure 4. Marimastat reversed hepatic steatosis and improved surrogate markers for insulin sensitivity in diet-induced obese mice
as well as in ob/ob animals. Mean hepatic fat fraction as measured by MR spectroscopy was decreased following Marimastat treatment (A).
Marimastat treatment resulted in a decrease of plasma alanine aminotransferase levels (B), indicating decreased hepatic injury. Glucose (C) and insulin
(D) levels in the fasted state, as well as log of homeostasis assessment (log(HOMA); E) and Quantitative insulin-sensitivity check index (QUICKI; F) as
surrogate markers for insulin sensitivity were improved following treatment with Marimastat. Values represent the mean 6 SEM. Statistical
significance is calculated between the VEH and MAR animals (n=5 C57BL/6 and n=4 ob/ob animals per group; *, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0025587.g004
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show that two weeks of Marimastat treatment almost completely
reverses the metabolic phenotype, compared to vehicle-treated
obese controls. These findings were validated in a second,
mechanistically different animal model of obesity and hepatic
steatosis using the murine model of leptin deficiency.
Adipokines, a group of polypeptide molecules primarily secreted
by adipose tissue exert local, peripheral and/or central actions and
are involved in the pathogenesis of NAFLD [35]. The cytokines
TNF-a and IL-6 are involved in induction of insulin and leptin
resistance and can be stimulated by the adipokine leptin (regulated
Figure 6. Relative mRNA expression of genes related to Timp3/TACE dyad (A) as well as expression of metabolic genes (B) in livers
of mice fed a 60% high fat diet, comparing vehicle and Marimastat treatment at two weeks. Relative transcript levels were quantified by
TaqMan quantitative RT-PCR, normalized by b2MG and expressed in arbitrary units versus 60% fat fed control animals at baseline (represented by the
dotted line). Values represent the mean 6 SEM. Statistical significance is calculated between the VEH and MAR animals (n= 5 animals per group; *,
P,0.05; **, P,0.01; ***, P,0.001; ns, not significant).
doi:10.1371/journal.pone.0025587.g006
Figure 5. Effects of Marimastat on serum adipokine levels, fatty acid export from the liver and TACE activity. C57BL/6 animals were fed
a high fat diet for 9 weeks, followed by two weeks of treatment with either Marimastat (MAR) or vehicle (VEH) control. Ob/ob animals were fed a
normal fat diet and received 4 weeks of MAR or VEH control. MAR did not affect serum levels of adiponectin (A), leptin (B) and tumor necrosis factor-a
receptor II (p75) (C); however, serum levels of IL-6 (D) were significantly increased in MAR animals in both studies. MAR did not affect hepatic lipid
export rates, as quantified by injection of tyloxapol (E). MAR inhibited both human and mouse recombinant TACE in a dose-dependent matter. Values
represent the mean6 SEM. Statistical significance is calculated between the VEH and MAR animals (n=5 C57BL/6 and n= 4 ob/ob animals per group;
*, P,0.05; **, P,0.01; ns, not significant).
doi:10.1371/journal.pone.0025587.g005
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by the ob gene), or inhibited by the adipokine adiponectin [35].
TACE, in part, regulates the production of TNF-a and IL-6, and
may indirectly affect release of adiponectin and leptin. Our data
demonstrates that despite efficient inhibition of TACE activity by
Marimastat, serum levels of the adipokines, adiponectin, leptin
and TNF-a receptor II remained unchanged. In contrast, serum
levels of IL-6 were significantly elevated following Marimastat
treatment. Because IL-6 is also involved in hepatic triglyceride
secretion [32], we hypothesized that the increase in IL-6 could
have contributed to the improvement of hepatic steatosis by
regulating hepatic fatty acid export by the liver. To address this,
we quantified hepatic lipid export by injecting tyloxapol, an
inhibitor of very low-density lipoprotein hydrolysis, and measured
serum triglyceride levels. The rate of very low-density lipoprotein
production was similar in both groups, indicating that Marimastat
treatment did not affect hepatic fatty acid export.
Pathways and mechanisms linking the TACE/TIMP-3 dyad to
insulin resistance and hepatic steatosis may involve expression of
proteins playing a role in fatty acid uptake, triglyceride synthesis
and methionine metabolism [20]. Hepatic gene expression analysis
in our study indicates that Marimastat treatment significantly
decreased transcript levels of genes related to fatty acid synthesis,
such as Acaca, Fasn, Scd1, Elovl6 and Srebf1, while Srepf2, a gene
involved in cholesterol synthesis, remained unchanged. Hepatic
transcript levels of genes involved in fatty acid oxidation such as
Ppara, Nr1h3 and Nr1h4 were slightly, but significantly, decreased
following Marimastat treatment. This was similar for hepatic gene
expression of Mttp and Apob, both involved in triglyceride export.
This data suggests that a significant inhibition of hepatic fatty acid
synthesis, in combination with relatively unchanged rates of fatty
acid oxidation and triglyceride export, may be, at least in part,
responsible for the beneficial effects of Marimastat in the reversal
of hepatic steatosis.
In a previous study, mice deficient in Timp3 had increased
activity of TACE and elevated levels of TNF, and developed
spontaneous, severe inflammation in the liver [36]. In addition,
following partial hepatectomy these mice succumbed to liver
failure, indicating the importance of TNF signaling in liver
regeneration [36]. In line with this data, we have previously
demonstrated that matrix metalloproteinases and TACE-inhibi-
tion by Marimastat significantly attenuated hepatic injury and
inflammation following carbon tetrachloride intoxication [37], but
may impair hepatic regeneration when administered concomi-
tantly [28]. Also, in a murine model of fat free diet-induced
essential fatty acid deficiency, we have demonstrated that
Marimastat treatment markedly prevented hepatic triglyceride
accumulation, despite elevated rates of de novo lipogenesis and
onset of essential fatty acid deficiency [38]. In the current paper,
Marimastat treatment ameliorated hepatic injury in both diet-
induced obese mice as well as in leptin deficient ob/ob animals,
corroborating our previous findings. More importantly, in the first
post-operative days following two-thirds hepatectomy in diet-
induced obese mice, Marimastat pre-treatment reversed hepatic
steatosis and decreased hepatic injury by about 50%. Liver growth
Figure 7. Reversal of established steatosis using Marimastat ameliorated post-operative liver injury, without affecting
regeneration. C57BL/6 animals were fed a high fat diet for 9 weeks, followed by two weeks of treatment with either Marimastat (MAR) or
vehicle (VEH) control. After reversal of steatosis (A), animals were subjected to a two-thirds hepatectomy. Marimastat did not affect speed of liver
regeneration, as measured by liver to body weight ratios over time (B). Post-operative liver injury was significantly decreased in diet-induced obese
animals that had their steatosis reversed following Marimastat treatment, as quantified by aspartate aminotransferase (AST; C) and alanine
aminotransferase (ALT; D). Values represent the mean 6 SEM. Statistical significance is calculated between the VEH and MAR animals (n=10 animals
per group per time point; *, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0025587.g007
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rate was not impaired, because Marimastat treatment was halted
24 hours prior to hepatic resection to avoid any potential effects of
TACE-inhibition on hepatic regeneration [28]. These findings
may deserve further experimental investigation in the search for a
pharmacologic treatment for the reversal of steatosis.
Although we cannot extrapolate our experimental in vivo results
with Marimastat to human clinical trials directly, it is possible that
Marimastat as well as other drugs with anti-TACE activity may
have similar effects on hepatic steatosis. Clinically, Marimastat has
been used in multiple oncologic clinical trials up to phase III;
however, its overall therapeutic benefit was limited and the trials
were halted [39–41]. A final note of caution is warranted when
patients with chronic, active liver diseases such as hepatitis or non-
alcoholic steatohepatitis receive long-term treatment with TACE
and matrix metalloproteinase-inhibitors, since inhibition of
fibrolytic matrix metalloproteinases will likely accelerate hepatic
fibrogenesis formation [37]. However, this is unlikely to cause a
problem in a short term treatment mode prior to surgery.
Nonetheless, the use of these drugs could still be used in those with
simple steatosis or for short periods of time, since the effects on
fibrogenesis may only apply to long-term use [37].
In conclusion, we demonstrated that TACE-activity inhibition
by Marimastat in two murine models of hepatic steatosis resulted
in reversal of steatosis, coupled with improvement of surrogate
markers of insulin sensitivity. Short-term use of Marimastat
decreased hepatic fat content of high fat-fed obese mice, and
subsequently attenuated hepatic injury following major hepatic
resection. Since effective inhibition of TACE activity improved
surgical outcome, our data suggests a potential use in patients with
steatosis who need to undergo major hepatic resection. Based on
these findings in animal models, we advocate further investigation
of pharmacologic TACE-inhibitors in human patients affected by
NAFLD.
Acknowledgments
The authors are grateful to graphic artist Kristin Johnson (Children’s
Hospital Boston, Boston, MA) for excellent assistance with photography.
Author Contributions
Conceived and designed the experiments: VdM YP MP. Performed the
experiments: VdM HL JM AS. Analyzed the data: VdM YP MP. Wrote
the paper: VdM MP.
References
1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221–1231.
2. Lazo M, Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a
global perspective. Semin Liver Dis 28: 339–350.
3. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH (2009) Systematic review
of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol
51: 371–379.
4. Jou J, Choi SS, Diehl AM (2008) Mechanisms of disease progression in
nonalcoholic fatty liver disease. Semin Liver Dis 28: 370–379.
5. Neuschwander-Tetri BA (2010) Hepatic lipotoxicity and the pathogenesis of
nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid
metabolites. Hepatology 52: 774–788.
6. Adam R, Hoti E (2009) Liver transplantation: the current situation. Semin Liver
Dis 29: 3–18.
7. de Meijer VE, Kalish BT, Puder M, IJzermans JNM (2010) Systematic review
and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg
97: 1331–1339.
8. Selzner M, Clavien PA (2001) Fatty liver in liver transplantation and surgery.
Semin Liver Dis 21: 105–113.
9. Vuppalanchi R, Chalasani N (2009) Nonalcoholic fatty liver disease and
nonalcoholic steatohepatitis: Selected practical issues in their evaluation and
management. Hepatology 49: 306–317.
10. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. (2010)
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl JMed
362: 1675–1685.
11. Sanyal AJ (2005) Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver
disease. Nat Clin Pract Gastroenterol Hepatol 2: 46–53.
12. Tilg H, Moschen AR (2008) Insulin resistance, inflammation, and non-alcoholic
fatty liver disease. Trends Endocrinol Metab 19: 371–379.
13. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:
860–867.
14. Murphy G, Murthy A, Khokha R (2008) Clipping, shedding and RIPping keep
immunity on cue. Trends Immunol 29: 75–82.
15. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Protection from
obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature
389: 610–614.
16. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, et al. (1997) A
metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from
cells. Nature 385: 729–733.
17. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, et al. (1997) Cloning of a
disintegrin metalloproteinase that processes precursor tumour-necrosis factor-
alpha. Nature 385: 733–736.
18. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, et al. (1998) TNF-
alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435: 39–44.
19. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR (2007) Insulin
stimulates the cleavage and release of the extracellular domain of Klotho by
ADAM10 and ADAM17. Proc Natl Acad Sci USA 104: 19796–19801.
20. Fiorentino L, Vivanti A, Cavalera M, Marzano V, Ronci M, et al. (2010)
Increased tumor necrosis factor alpha-converting enzyme activity induces insulin
resistance and hepatosteatosis in mice. Hepatology 51: 103–110.
21. Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, et al. (2009)
Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and
adipose tissue inflammation in mice. Gastroenterology 136: 663–672.
22. Doggrell SA (2002) TACE inhibition: a new approach to treating inflammation.
Expert Opin Investig Drugs 11: 1003–1006.
23. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K (2002) Effect of
TNF-alpha–converting enzyme inhibitor on insulin resistance in fructose-fed
rats. Hypertension 39: 578–580.
24. de Meijer VE, Le HD, Meisel JA, Sharif MR, Pan A, et al. (2010) Dietary fat
intake promotes the development of hepatic steatosis independently from excess
caloric consumption in a murine model. Metabolism 59: 1092–1105.
25. de Meijer VE, Le HD, Meisel JA, Puder (2010) Repetitive orogastric gavage
affects the phenotype of diet-induced obese mice. Physiol Behav 100:
387–393.
26. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, et al. (1995) Weight-
reducing effects of the plasma protein encoded by the obese gene. Science 269:
543–546.
27. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, et al. (1995)
Effects of the obese gene product on body weight regulation in ob/ob mice.
Science 269: 540–543.
28. Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, et al. (2008) A critical
role for matrix metalloproteinases in liver regeneration. J Surg Res 145:
192–198.
29. Greene AK, Puder M (2003) Partial hepatectomy in the mouse: technique and
perioperative management. J Invest Surg 16: 99–102.
30. Muniyappa R, Lee S, Chen H, Quon MJ (2008) Current approaches for
assessing insulin sensitivity and resistance in vivo: advantages, limitations, and
appropriate usage. Am J Physiol Endocrinol Metab 294: E15–26.
31. Otway S, Robinson DS (1967) The use of a non-ionic detergent (Triton WR
1339) to determine rates of triglyceride entry into the circulation of the rat under
different physiological conditions. J Physiol 190: 321–332.
32. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, et al. (2004) Interleukin 6
alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty
liver disease. Hepatology 40: 933–941.
33. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, et al. (2005)
Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes
and vascular inflammation via increased TNF-alpha. J Clin Invest 115:
3494–3505.
34. Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, et al. (2007)
Mice heterozygous for tumor necrosis factor-alpha converting enzyme are
protected from obesity-induced insulin resistance and diabetes. Diabetes 56:
2541–2546.
35. Marra F, Bertolani C (2009) Adipokines in liver diseases. Hepatology 50:
957–969.
36. Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, et al. (2004)
Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation
and failure of liver regeneration. Nat Genet 36: 969–977.
37. de Meijer VE, Sverdlov DY, Popov Y, Le HD, Meisel JA, et al. (2010) Broad-
spectrum matrix metalloproteinase inhibition curbs inflammation and liver
injury but aggravates experimental liver fibrosis in mice. PLoS One 5: e11256.
38. Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian BR, et al. (2006)
Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and
prevents dietary-induced hepatic steatosis and injury in a murine model.
Am J Physiol Gastrointest Liver Physiol 291: G1011–1019.
TACE-Inhibition Reverses Hepatic Steatosis
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25587
39. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, et al. (2002)
Marimastat as maintenance therapy for patients with advanced gastric cancer: a
randomised trial. Br J Cancer 86: 1864–1870.
40. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase
inhibitors and cancer: trials and tribulations. Science 295: 2387–2392.
41. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, et al. (2005)
Marimastat in the treatment of patients with biochemically relapsed prostate
cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer
Res 11: 4437–4443.
TACE-Inhibition Reverses Hepatic Steatosis
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e25587
